HSCS · HeartSciences Inc.
$2.99
-0.13 (-4.17%)
At close · Aug 28
Going-concern doubt
— flagged Jul 23, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our independent registered public accounting firm has issued an opinion on our audited financial statements included in this Annual Report on Form 10-K that contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern because we have experienced recurring losses, negative cash flows from operations, and limited capital resources. These events and conditions indicate that a material uncertainty exists that may cast significant doubt on our ability to continue as a going concern.”View the 10-K filed Jul 23, 2026
Market Cap
$12.17M
Shares
3.90M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$4319
-0.7%
FY2026
Net Income
-$9.14M
-4.3%
FY2026
Gross Margin
59.06%
+2.3pp
FY2026
Operating Margin
-194787.38%
-2774.2pp
FY2026
Diluted EPS
-$9.34
+50.2%
FY2025
Operating Cash Flow
-$7.43M
-0.2%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|---|
| — | $4319 | $4350 | $18.6K | $5150 | $14.37K | |
| — | $1768 | $1880 | $6081 | $2796 | $7890 | |
| — | $2551 | $2470 | $12.52K | $2354 | $6483 | |
| — | 59.06% | 56.78% | 67.31% | 45.71% | 45.11% | |
| — | $2.84M | $4.39M | $2.88M | $2.46M | $3M | |
| — | $5.58M | $3.97M | $3.44M | $3.65M | $1.71M | |
| — | $8.42M | $8.36M | $6.32M | $6.12M | $4.72M | |
| — | -$8.41M | -$8.35M | -$6.31M | -$6.11M | -$4.71M | |
| — | -194787.38% | -192013.13% | -33901.99% | -118698.33% | -32765.6% | |
| — | $753.04K | $500.45K | $354.08K | $243.17K | $371.62K | |
| — | -$729.01K | -$412.66K | -$299.44K | -$241.33K | -$118.86K | |
| — | $0 | $0 | — | — | — | |
| — | -$9.14M | -$8.77M | -$6.61M | -$6.35M | -$4.83M | |
| — | -211666.47% | -201499.52% | -35511.87% | -123384.27% | -33592.57% | |
| USD/shares | — | -$3.48 | -$9.34 | -$18.74 | -$80.00 | -$145.00 |
| USD/shares | -$6.86 | — | -$9.34 | -$18.74 | -$80.00 | -$145.00 |
| shares | — | 2.63M | 938.26K | 352.52K | 79.51K | 33.19K |
| shares | — | — | 938.26K | 352.52K | 79.51K | 33.19K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.36×
EV/EBIT
—
Peer median 34.37×
P/E (TTM)
—
Peer medians compare against the 63 similar-size Medical Devices companies (of 141 listed).
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2026 | FY2025 |
|---|---|---|
| Single Reportable Segment | -$8,412,867 | -$8,352,571 |
Key facts
CIK
1468492
CUSIP
42254E302
13F (30d)
15 filings
15 filers
Visit website
Investor relations